Abstract
Background: Isolated organ perfusion with hyperthermia and melphalan with or without tumor necrosis factor-a has been effectively used to treat regionally confined, unresectable malignancies of both the limb and liver. Many patients, however, will eventually relapse at distant sites. We used reverse transcription-polymerase chain reaction (RT-PCR) to determine whether significant tumor microembolization occurs in patients undergoing isolated limb perfusion (ILP), isolated hepatic perfusion (IHP), or hepatic resection.
Methods: Primers specific for the human tyrosinase gene or carcinoembryonic antigen gene were designed for RT-PCR to screen melanoma or colon adenocarcinoma, respectively. RNA from human melanoma lines (Pmel and 1286) and human colon adenocarcinoma lines (H508 and HT29) were used to generate positive control cDNA. Normal human blood was inoculated with tumor cells at concentrations that ranged from 1022 to 105 tumor cells/ml of blood to define the sensitivity. Systemic and perfusate blood samples were drawn from 15 patients (8 patients underwent IHP, 5 patients underwent ILP, and 2 patients underwent resection) before the start of the operation, immediately before and during the perfusion, and postoperatively. Mononuclear cell fractions were separated from the blood samples and RNA was extracted for the RT-PCR assay. Standard primers for human b-actin were used to confirm that cDNA was generated after the RT reaction.
Results: RT-PCR assay sensitivity was determined to be 10 tumor cells/ml of whole blood. Of the 8 IHP patients, 6 had colon metastases and 2 had ocular melanoma metastases to the liver. All 5 ILP patients had in transit melanoma of the extremity. Two patients with colon metastases to the liver were found to have resectable disease. There were no detectable circulating tumor cells in the systemic circulation either preoperatively or postoperatively in all 15 patients that were screened.
Conclusions: RT-PCR is a highly sensitive method of detecting tumor cells in perfusate or blood. Manipulation of the limb or liver followed by resection or isolated hyperthermic perfusion does not cause detectable release of circulating tumor cells. The late development of distant metastases observed in many of these patients does not correlate with the ability to measure circulating tumor cells during regional therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
REFERENCES
Lienard D, Ewalenko P, Delmotte JJ, et al. 1992 High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–60.
Lienard D, Eggermont AM, Schraffordt-Koops H, et al. 1994 Isolated perfusion of the limb with high-dose tumor necrosis factor, interferon gamma and melphalan for melanoma stage III: results of a multicentre pilot study. Melanoma Res 4:21–26.
Eggermont AMM, Koops HS, Lie’nard D, et al. 1996 Isolated limb perfusion with high dose tumor necrosis factor-a in combination with interferon-gamma and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653–2665.
Eggermont AM, Schraffordt KH, Klausner JM, et al. 1997 Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res 91:189 –203.
Alexander HR, Bartlett DL, Libutti SK. 1998 Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am 4:2–11.
Alexander HR, Bartlett DL, Libutti SK, et al. 1998Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16:1479–1489.
Klaase JM, Kroon BBR, van Geel AN, et al. 1994 Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 115:39–45.
Smith B, Selby P, Southgate J, et al. 1991 Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338:1227–1229.
Pittman K, Burchill S, Smith B, et al. 1996 Reverse transcriptasepolymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 7:297–301.
Jung FA, Buzaid AC, Ross MI, et al. 1997 Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 15:2826–2831.
Glaser R, Rass K, Seiter S, et al. 1997 Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15:2818–2825.
Bostick PJ, Hoon DS, Cote RJ. 1998 Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer. N Engl J Med 339:1643–1644.
Gerhard M, Johl H, Kalthoff H, et al. 1994 Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12:725–729.
Mori M, Mimori K, Ueo H, et al. 1998 Clinical significance of molecular detection of carcinoma cell in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 16:128–132.
Seiden MV, Kantoff PW, Krithivas K, et al. 1994 Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12:2634–2639.
Peck K, Sher YP, Shih JY, et al. 1998 Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 58:2761–2765.
Ko Y, Klinz M, Totzke G, et al. 1998 Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin Cancer Res 4:2141–2146.
Thom AK, Alexander HR, Andrich MP, et al. 1995 Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 13:264–273.
Hanckom GS, Johnson CA, Kidson SH. 1997 An improved and combined reverse transcription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res 7:111–116.
Foss AJ, Guille MJ, Occleston NL, et al. 1995 The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 72:155–159.
Daly JM, Kemeny NE. 1997 Metastatic cancer to the liver. In: DeVita VT, Hellman S, Rosenberg SA, Cancer: principles and practice of oncology. Lippincott-Raven Philadelphia 2551–2570.
Jonas W, Windeatt S, O-Boateng A, et al. 1996 Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase polymerase chain reaction. Gut 39:717–721.
Mellado B, Colomer D, Castel T, et al. 1996 Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14:2091–2097.
Zhang Y, Zippe CD, VanLente F, et al. 1999 Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostatespecific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 3:1215–1220.
Henke W, Jung M, Jung K, et al. 1999 Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 70:52–56.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, P.C., McCart, A., Hewitt, S.M. et al. Isolated Organ Perfusion Does Not Result in Systemic Microembolization of Tumor Cells. Ann Surg Oncol 6, 658–663 (1999). https://doi.org/10.1007/s10434-999-0658-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-999-0658-3